KM Pharmaceutical's Largest Shareholder Purchases Additional Shares, "Strengthening Responsible Management"

The largest shareholder of KM Pharmaceutical has once again emphasized the company's commitment to enhancing corporate value and responsible management by purchasing additional shares.

KM Pharmaceutical announced on the 22nd that Chairman Kang Ilmo, its largest shareholder, recently acquired 1,490 common shares through an on-market purchase. As a result of this acquisition, Chairman Kang's stake has increased to 37.64%.

The company explained that this increase in shareholding reflects confidence in KM Pharmaceutical's transition to a life care-focused business and its medium- to long-term growth strategy.

In particular, the company highlighted the significance of the largest shareholder's share purchase at a time when it is accelerating strategies to strengthen business competitiveness, including brand renewal, the advancement of its product portfolio, and securing new growth drivers.

KM Pharmaceutical stated that this share purchase is not simply about increasing ownership, but also demonstrates the commitment of the largest shareholder and management to responsible management based on their confidence in the company's future growth potential.

A company representative said, "The increase in the largest shareholder's stake demonstrates our determination to execute current business strategies and our confidence in growth. Strengthening the competitiveness of our existing OEM·ODM business, while establishing a foundation for sustainable growth, will be key outcomes of this decision."

The representative added, "Going forward, we will work to enhance market trust through active communication with shareholders and investors, and strive to increase shareholder value by improving performance and generating results in new business areas."

Meanwhile, KM Pharmaceutical is moving away from its traditional focus as an OEM·ODM company in the oral care and lifestyle beauty sectors, and is working to transform itself into a life care brand company that appeals to a broader range of consumers.

The company plans to secure new growth engines by focusing on strengthening product competitiveness centered on functionality and ingredients, nurturing new brands, and expanding into domestic and overseas markets.

With the largest shareholder's increased stake as a catalyst, KM Pharmaceutical expects to further strengthen management stability and execution of growth strategies, accelerating its leap into becoming a leading life care company.

This content was produced with the assistance of AI translation services.